A Journal of Postdoctoral Research.
     Login   |   Register   
    ISSN : 2328-9791
left right
Hall of Fame
Address 1 :
Address 2 :
Title : Dr.
First Name : RAJESH
Last Name : KUMAR
University/Institution : Dana-Farber Cancer Institute
Email ID : rajesh_kumar@dfci.harvard.edu
City : Boston
Country : United States
State : Massachusetts
Zipcode : 02140
Department : Pediatric Oncology
Company Name :
Area of Research
Area of Expertise
Ovarian cancer
Brief Description of Research Interest :

Rajesh obtained his PhD from University of Lausanne, Switzerland in Molecular Biology and Immunology. His thesis project was to understand the mechanism of pathogenesis in endometriosis, a benign gynecological disorder which primarily causing infertility in women and to find a novel therapy for Endometriosis. Rajesh is also a recipient of Swiss National Science Foundation(SNSF) fellowship, a highly competitive fellowship awarded to the most promising candidate from Switzerland to go abroad. His postdoctoral research includes understanding the mechanisms involved in chemoresistance in ovarian cancer and exploring the possibility to overcome the resistance.

Representative Publications :

1. How can molecular abnormalities influence our clinical approach.  Wei W, Giulia F, Luffer S, Kumar R, Wu B, Tavallai M, Bekele RT, Birrer MJ. Ann Oncol. 2017 Nov 1;28(suppl_8):viii16-viii24.

2. Update on Dendritic Cell-Induced Immunological and Clinical Tolerance.   Obregon C*, Kumar R*, Pascual MA, Vassalli G, Golshayan D. Front Immunol. 2017; 8: 421. *shared first co-author

3. Targeted gamma-secretase inhibition of Notch signaling activation in acute renal injury.  Wyss JC, Kumar R, Mikulic J, Schneider M, Aebi JD, Juillerat-Jeanneret L, Golshayan D.  American journal of physiology. Renal physiology. 2017; ajprenal.00414.2016. 

4. IL-2-Mediated In Vivo Expansion of Regulatory T Cells Combined with CD154–CD40 but Not CTLA-4 Ig Prolongs Co-Stimulation Blockade Allograft Survival in Naive and Sensitized Mice. Govender L, Wyss JC, Kumar R, Pascual M and Golshayan D Front Immunol. 2017 Apr 21;8:421. doi: 10.3389/fimmu.2017.00421. eCollection 2017.

5. Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases. Kumar R, Juillerat-Jeanneret L, Golshayan D.  J Med Chem. 2016 Sep 8;59(17):7719-37.

6. Targeted γ-Secretase Inhibition to Control the Notch Pathway in Renal Diseases.    Juillerat-Jeanneret L, Flohr A, Schneider M, Walter I, Wyss JC, Kumar R, Golshayan D, Aebi JD. J Med Chem. 2015 Oct 22;58(20):8097-109. 

7. Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling. KumarR, Clerc AC, Gori I, Russell R, Pellegrini C, Govender L, Wyss JC, Golshayan D*, Canny GO*. PLoS One. 2014 Feb 24; 9(2):e89742.

8. Compartmentalized secretory leukocyte protease inhibitor expression and hormone responses    along the reproductive tract of postmenopausal women. Kumar R, Vicari M, Gori I, Achtari C, Fiche M, Surbeck I, Damnon F, Canny GO.  J Reprod Immunol. 2011 Dec;92(1-2):88-96.

9. Lipoxin A4is a novel estrogen receptor modulator.     Russell R, Gori I, Pellegrini C, Kumar R, Achtari C, Canny GO. FASEB J. 2011 Dec;25(12):4326-37. 


home phone mail info@postdocjournal.com
twitter facebook social icon Social link You Tube sky
Click Here